The safety of flurbiprofen, a new non-steroidal anti-inflammatory drug was tested in individuals with G-6-PD deficiency. The study was carried out in vitro evaluating the erythrocyte levels of reduced glutathione under basal conditions and after incubation with the drug or acetylphenyl-hydrazine. In the red cells marked with 51Cr, survival was evaluated in vivo before and during flurbiprofen administration. The study shows that flurbiprofen has no oxidating activity in carriers of the G-6-PD Mediterranean variant.
Safety of flurbiprofen in subjects with G-6-PD deficiency. In vivo and in vitro results / Passiu, G; Mela, Q; Perpignano, G; Frigerio, R; Cacace, E. - In: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH. - ISSN 0251-1649. - 4:2(1984), p. 137-9.
Safety of flurbiprofen in subjects with G-6-PD deficiency. In vivo and in vitro results
Passiu, G;
1984-01-01
Abstract
The safety of flurbiprofen, a new non-steroidal anti-inflammatory drug was tested in individuals with G-6-PD deficiency. The study was carried out in vitro evaluating the erythrocyte levels of reduced glutathione under basal conditions and after incubation with the drug or acetylphenyl-hydrazine. In the red cells marked with 51Cr, survival was evaluated in vivo before and during flurbiprofen administration. The study shows that flurbiprofen has no oxidating activity in carriers of the G-6-PD Mediterranean variant.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
